Literature DB >> 19490807

Radiological sinonasal findings in adults with cystic fibrosis.

Richard R Orlandi1, Richard H Wiggins.   

Abstract

BACKGROUND: Care of cystic fibrosis (CF) patients has extended the expected survival far into adulthood. The morphological changes of adult CF patients' paranasal sinuses have not been thoroughly addressed.
METHODS: A retrospective review was performed of computed tomography imaging of adult CF patients at an academic medical center. Developmental changes, bone sclerosis, mucoceles, and degree of inflammation (using a modified Lund-Mackay scoring system) were assessed.
RESULTS: Forty-five patients were included in the study. The majority of frontal and sphenoid sinuses were either aplastic or hypoplastic. Maxillary hypoplasia was less commonly seen. Seven patients had mucoceles. Sclerosis of the sinuses was a common finding, affecting 84.4% of patients. Inflammation of the sinuses was also common, with a median modified Lund-Mackay score of 15.0 (out of a median 20 possible).
CONCLUSION: Poor development of the sinuses seen in pediatric CF patients persists into adulthood. Inflammation of the sinuses is a common finding. Bone sclerosis, likely caused by chronic inflammation, affects a large majority of these patients.

Entities:  

Mesh:

Year:  2009        PMID: 19490807     DOI: 10.2500/ajra.2009.23.3324

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  2 in total

1.  Total aplasia of the paranasal sinuses.

Authors:  Hakan Korkmaz; Mukadder Korkmaz
Journal:  Allergy Rhinol (Providence)       Date:  2013

2.  Critical Evaluation of Sinonasal Disease in 64 Adults with Primary Ciliary Dyskinesia.

Authors:  Emilie Bequignon; Laurence Dupuy; Francoise Zerah-Lancner; Laurence Bassinet; Isabelle Honoré; Marie Legendre; Marie Devars du Mayne; Virginie Escabasse; Bruno Crestani; Bernard Maître; Estelle Escudier; André Coste; Jean-François Papon
Journal:  J Clin Med       Date:  2019-05-07       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.